President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoKyle Diamantas <1%
Stephen Hahn <1%
Brett Giroir <1%
Grace Graham <1%
$39,291 Wol.
$39,291 Wol.
Dec 30, 2026
Kyle Diamantas
No
Stephen Hahn
No
Brett Giroir
No
Grace Graham
No
Sara Brenner
No
No announcement by December 31
No
Kyle Diamantas <1%
Stephen Hahn <1%
Brett Giroir <1%
Grace Graham <1%
$39,291 Wol.
$39,291 Wol.
Dec 30, 2026
Kyle Diamantas
$10,368 Wol.
No
Stephen Hahn
$5,255 Wol.
No
Brett Giroir
$5,265 Wol.
No
Grace Graham
$6,713 Wol.
No
Sara Brenner
$8,024 Wol.
No
No announcement by December 31
$3,664 Wol.
No
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Rynek otwarty: May 12, 2026, 7:59 PM ET
Wolumen
$39,291Data zakończenia
Dec 31, 2026Rynek otwarty
May 12, 2026, 7:59 PM ETRozstrzygający
0x69c47De9D...Wynik zaproponowany: No
Brak sporu
Ostateczny wynik: No
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Wolumen
$39,291Data zakończenia
Dec 31, 2026Rynek otwarty
May 12, 2026, 7:59 PM ETRozstrzygający
0x69c47De9D...Wynik zaproponowany: No
Brak sporu
Ostateczny wynik: No
President Trump's search for a permanent FDA commissioner remains fluid following Marty Makary's May 2026 resignation, leaving Kyle Diamantas as acting commissioner while White House aides review multiple finalists including policy adviser Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Trader odds stay dispersed because the process is still in vetting without a confirmed frontrunner, Senate confirmation timeline, or binding deadline before year-end. Key differentiators among mentioned names such as former commissioner Stephen Hahn, Brett Giroir, Grace Graham, and Sara Brenner include prior FDA or HHS leadership, oncology or regulatory expertise, and alignment with current administration priorities on drug approvals, food safety, and industry relations. Support could consolidate behind one candidate through Senate vote counts, direct White House endorsement, or demonstrated ability to navigate confirmation hearings in an election year.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania